Table 1.
Patient characteristics in the cohort study according to the treatment options (n = 120).
| n (%) | Trastuzumab-plus-chemotherapy group (n = 36) |
Trastuzumab-monotherapy group (n = 52) |
Non-trastuzumab group (n = 32) |
P | ||
|---|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | ||||
| Age | <75 | 70 (58.3) | 26 (72.2) | 27 (51.9) | 17 (53.1) | 0.13 |
| ≧75 | 50 (41.7) | 10 (27.8) | 25 (48.1) | 15 (46.9) | ||
| Stage | I | 51 (42.5) | 14 (38.9) | 20 (38.5) | 17 (53.1) | 0.43 |
| IIA | 49 (40.8) | 16 (44.4) | 22 (42.3) | 11 (34.4) | ||
| IIB | 16 (13.3) | 5 (13.9) | 9 (13.7) | 2 (6.3) | ||
| IIIA | 4 (3.3) | 1 (2.8) | 1 (1.9) | 2 (6.3) | ||
| Surgery | Mastectomy | 82 (68.3) | 22 (61.1) | 37 (71.2) | 23 (71.9) | 0.99 |
| Partial mastectomy | 38 (31.7) | 14 (38.9) | 15 (28.8) | 9 (28.1) | ||
| Lymph node metastasis | Negative | 82 (68.3) | 23 (63.9) | 35 (67.3) | 24 (75.0) | 0.88 |
| Positive | 37 (30.8) | 12 (33.3) | 17 (32.7) | 8 (25.0) | ||
| N.A | 1 (0.8) | 1 (2.8) | 0 (0) | 0 (0) | ||
| Pathology | Invasive ductal carcinoma | 112 (93.3) | 32 (88.9) | 49 (94.2) | 31 (96.9) | 0.85 |
| Invasive lobular carcinoma | 5 (4.2) | 1 (2.8) | 3 (5.8) | 1 (3.1) | ||
| Special type | 3 (2.5) | 3 (8.3) | 0 (0) | 0 (0) | ||
| ER+ and/or PgR+ | Positive | 68 (56.7) | 17 (47.2) | 25 (48.1) | 26 (81.3) | 0.005 |
| Negative | 52 (43.3) | 19 (52.8) | 27 (51.9) | 6 (18.8) | ||
| Performance Status | 0 | 109 (90.8) | 34 (94.4) | 45 (86.5) | 30 (93.8) | 0.36 |
| 1 | 11 (9.2) | 2 (5.6) | 7 (13.5) | 2 (6.3) | ||
| Major Comorbidity | ||||||
| Hypertension | No | 74 (61.7) | 23 (63.9) | 30 (57.7) | 21 (65.6) | 0.73 |
| Yes | 46 (38.3) | 13 (36.1) | 22 (42.3) | 11 (34.4) | ||
| Diabetes | No | 105 (87.5) | 31 (86.1) | 48 (92.3) | 26 (81.2) | 0.32 |
| Yes | 15 (12.5) | 5 (13.9) | 4 (7.7) | 6 (18.8) | ||
| Osteoporosis | No | 108 (90.0) | 32 (88.9) | 47 (90.5) | 29 (90.6) | 0.97 |
| Yes | 12 (10.0) | 4 (11.1) | 5 (9.6) | 3 (9.4) | ||
| Hyperlipidaemia | No | 95 (79.2) | 27 (75.0) | 41 (78.8) | 27 (84.4) | 0.64 |
| Yes | 25 (20.8) | 9 (25.0) | 11 (21.2) | 5 (15.6) | ||
N.A: Non available.